Sensei Biotherapeutics (NASDAQ:FTH) Posts Earnings Results, Misses Expectations By $0.13 EPS

Sensei Biotherapeutics (NASDAQ:FTH) posted its quarterly earnings data on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13), Zacks reports.

Sensei Biotherapeutics Stock Performance

Shares of FTH traded up $0.70 during mid-day trading on Tuesday, reaching $19.93. The company’s stock had a trading volume of 16,869 shares, compared to its average volume of 251,708. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The firm has a market capitalization of $514.94 million, a PE ratio of -0.14 and a beta of -0.14. The stock’s fifty day moving average price is $28.55.

Analysts Set New Price Targets

A number of research firms recently commented on FTH. William Blair initiated coverage on Sensei Biotherapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 price target for the company. Lifesci Capital upgraded Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, October 15th. BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, October 27th. Finally, TD Cowen assumed coverage on Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $56.25.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.